Cargando…

Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*

OBJECTIVE: To investigate temporal trends and outcomes associated with early antibiotic prescribing in patients hospitalized with COVID-19. DESIGN: Retrospective propensity-matched cohort study using the National COVID Cohort Collaborative (N3C) database. SETTING: Sixty-six health systems throughout...

Descripción completa

Detalles Bibliográficos
Autores principales: Widere, J. Christian, Davis, Claire Leilani, Loomba, Johanna Jean, Bell, Taison D., Enfield, Kyle B., Barros, Andrew Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426778/
https://www.ncbi.nlm.nih.gov/pubmed/37125800
http://dx.doi.org/10.1097/CCM.0000000000005901
_version_ 1785090130381373440
author Widere, J. Christian
Davis, Claire Leilani
Loomba, Johanna Jean
Bell, Taison D.
Enfield, Kyle B.
Barros, Andrew Julio
author_facet Widere, J. Christian
Davis, Claire Leilani
Loomba, Johanna Jean
Bell, Taison D.
Enfield, Kyle B.
Barros, Andrew Julio
author_sort Widere, J. Christian
collection PubMed
description OBJECTIVE: To investigate temporal trends and outcomes associated with early antibiotic prescribing in patients hospitalized with COVID-19. DESIGN: Retrospective propensity-matched cohort study using the National COVID Cohort Collaborative (N3C) database. SETTING: Sixty-six health systems throughout the United States that were contributing to the N3C database. Centers that had fewer than 500 admissions in their dataset were excluded. PATIENTS: Patients hospitalized with COVID-19 were included. Patients were defined to have early antibiotic use if they received at least 3 calendar days of intravenous antibiotics within the first 5 days of admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 322,867 qualifying first hospitalizations, 43,089 patients received early empiric antibiotics. Antibiotic use declined across all centers in the data collection period, from March 2020 (23%) to June 2022 (9.6%). Average rates of early empiric antibiotic use (EEAU) also varied significantly between centers (deviance explained 7.33% vs 20.0%, p < 0.001). Antibiotic use decreased slightly by day 2 of hospitalization and was significantly reduced by day 5. Mechanical ventilation before day 2 (odds ratio [OR] 3.57; 95% CI, 3.42–3.72), extracorporeal membrane oxygenation before day 2 (OR 2.14; 95% CI, 1.75–2.61), and early vasopressor use (OR 1.85; 95% CI, 1.78–1.93) but not region of residence was associated with EEAU. After propensity matching, EEAU was associated with an increased risk for in-hospital mortality (OR 1.27; 95% CI, 1.23–1.33), prolonged mechanical ventilation (OR 1.65; 95% CI, 1.50–1.82), late broad-spectrum antibiotic exposure (OR 3.24; 95% CI, 2.99–3.52), and late Clostridium difficile infection (OR 1.60; 95% CI, 1.37–1.87). CONCLUSIONS: Although treatment of COVID-19 patients with empiric antibiotics has declined during the pandemic, the frequency of use remains high. There is significant inter-center variation in antibiotic prescribing practices and evidence of potential harm. Our findings are hypothesis-generating and future work should prospectively compare outcomes and adverse events.
format Online
Article
Text
id pubmed-10426778
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104267782023-08-16 Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study* Widere, J. Christian Davis, Claire Leilani Loomba, Johanna Jean Bell, Taison D. Enfield, Kyle B. Barros, Andrew Julio Crit Care Med Clinical Investigations OBJECTIVE: To investigate temporal trends and outcomes associated with early antibiotic prescribing in patients hospitalized with COVID-19. DESIGN: Retrospective propensity-matched cohort study using the National COVID Cohort Collaborative (N3C) database. SETTING: Sixty-six health systems throughout the United States that were contributing to the N3C database. Centers that had fewer than 500 admissions in their dataset were excluded. PATIENTS: Patients hospitalized with COVID-19 were included. Patients were defined to have early antibiotic use if they received at least 3 calendar days of intravenous antibiotics within the first 5 days of admission. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 322,867 qualifying first hospitalizations, 43,089 patients received early empiric antibiotics. Antibiotic use declined across all centers in the data collection period, from March 2020 (23%) to June 2022 (9.6%). Average rates of early empiric antibiotic use (EEAU) also varied significantly between centers (deviance explained 7.33% vs 20.0%, p < 0.001). Antibiotic use decreased slightly by day 2 of hospitalization and was significantly reduced by day 5. Mechanical ventilation before day 2 (odds ratio [OR] 3.57; 95% CI, 3.42–3.72), extracorporeal membrane oxygenation before day 2 (OR 2.14; 95% CI, 1.75–2.61), and early vasopressor use (OR 1.85; 95% CI, 1.78–1.93) but not region of residence was associated with EEAU. After propensity matching, EEAU was associated with an increased risk for in-hospital mortality (OR 1.27; 95% CI, 1.23–1.33), prolonged mechanical ventilation (OR 1.65; 95% CI, 1.50–1.82), late broad-spectrum antibiotic exposure (OR 3.24; 95% CI, 2.99–3.52), and late Clostridium difficile infection (OR 1.60; 95% CI, 1.37–1.87). CONCLUSIONS: Although treatment of COVID-19 patients with empiric antibiotics has declined during the pandemic, the frequency of use remains high. There is significant inter-center variation in antibiotic prescribing practices and evidence of potential harm. Our findings are hypothesis-generating and future work should prospectively compare outcomes and adverse events. Lippincott Williams & Wilkins 2023-09 2023-05-01 /pmc/articles/PMC10426778/ /pubmed/37125800 http://dx.doi.org/10.1097/CCM.0000000000005901 Text en Copyright © 2023 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Clinical Investigations
Widere, J. Christian
Davis, Claire Leilani
Loomba, Johanna Jean
Bell, Taison D.
Enfield, Kyle B.
Barros, Andrew Julio
Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title_full Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title_fullStr Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title_full_unstemmed Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title_short Early Empiric Antibiotic Use in Patients Hospitalized With COVID-19: A Retrospective Cohort Study*
title_sort early empiric antibiotic use in patients hospitalized with covid-19: a retrospective cohort study*
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426778/
https://www.ncbi.nlm.nih.gov/pubmed/37125800
http://dx.doi.org/10.1097/CCM.0000000000005901
work_keys_str_mv AT widerejchristian earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy
AT davisclaireleilani earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy
AT loombajohannajean earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy
AT belltaisond earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy
AT enfieldkyleb earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy
AT barrosandrewjulio earlyempiricantibioticuseinpatientshospitalizedwithcovid19aretrospectivecohortstudy